Drawing for OPTICYTE

USPTO serial 90025742

OPTICYTE

Reviewed by CopyMark Law Group

Reg. 6256450Status 702Renewal
Filing date
Status date
Registration date
Jan 26, 2021
Examiner
BROWN, BARBARA TROFFKIN
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with OPTICYTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Karen Hahn

8311 BRIER CREEK PARKWAY; SUITE 105277RALEIGH, NC 27617United States

Goods and services

ClassDescriptionStatusFirst use
005Human biological amniotic membrane or other postpartum tissues intended for subsequent implantation; human biological amniotic tissue or other postpartum tissues that may include amniotic membrane, amniotic fluid, umbilical cord, or placenta, intended for medical use for the treatment or prevention of ophthalmic diseases, or the treatment of wounds, ulcers, burns, scars and surgical incisions involving the eye; human biological tissue, namely, placental-derived tissue for use in biological tissue grafts for use in surgery and wound repair involving the eye; topical treatment in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions involving the eye, and the treatment or prevention of ophthalmic diseases; topical treatment made from amniotic material in the nature of a wound dressing for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions involving the eye; topical treatment made from amniotic material in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions involving the eye; wound treatment in the nature of amniotic material prepared in sheet forms or viscous formsACTIVEMay 5, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 29, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jul 29, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jul 27, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 24, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Jan 26, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 25, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 26, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 10, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 10, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 21, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 30, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 30, 2020DOCKASSIGNED TO EXAMINER—
Jul 25, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 2, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance